I would like to focus attention first on three major and immediate problem areas inherent in any testing system and then to discuss to a limited extent a major problem, generally not discussed, involved in the elucidation of the meaningfulness of any test system for human health and welfare.
The three problem areas I wish to discuss first are: (1) the toxic agent-the suspect compound; (2) the target-the tissue likely to develop the toxic response; and (3) the time factors involved in test systems.
There are three questions that must be asked regarding the toxic agent. What chemical is the toxic agent? How much of that agent is present? How long is that agent present? These questions must be asked whether one is doing an experiment on Neurospora, on human cells in vitro, on laboratory animals, individually on man, or on the human population. In more classical terminology, the question of the identity of the agent refers to studies on metabolic alterations of the compounds by cellular activity. The question of amount or concentration of agent is the function of not only the metabolism but also the distribution and the It is important to recognize that metabolic alteration of administered compounds may occur in the gut even before absorption has occurred. This may vary between species or within species; variation may even occur in the same individual at different times and on different diets. We are all familiar with the fact that sodium cyclamate becomes the more toxic cyclohexylamine by action of bacteria in the gastrointestinal tract. It is also becoming increasingly apparent that there are sites of metabolism in the vertebrate body beyond the liver. The lung, the testes, the kidney, and other organs may play important roles in the metabolism of the administered compound.
The age and the sex of the animals can be important. These and other physiological factors can influence the metabolism of foreign compounds. Factors external to the animal may also be important. The ability of one therapeutic drug to affect the metabolisrim drastically and therefore alter the toxicity or activity of a second therapeutic drug is now well known. It seems likely that this will be demonstrated for environmental chemicals. Thus, in the design of meaningful and effective test systems and in the extrapolation of data from these test systems to man, one must constantly ask whether the agent being tested is the original compound or one or more metabolites.
The second major concern is how much of the compound-be it the original agent or a more toxic metabolite-is in contact with the target tissue. Here it is necessary to look at what is described as the pharmacokinetics of a compound. This includes a variety of factors. The rate of absorption through the skin, the lungs, or the gastrointestinal tract is important. It must be recognized that the hydrogen ion concentration of the stomach can affect the rate and extent of absorption of partially ionized compounds. For slowly absorbed compounds, the gastrointestinal tract surface to volume ratio and transit time can be of considerable importance, and these vary among species. The route of administration in the experimental situation may be important. There is good evidence that after an intraperitoneal injection almost all of the compound flows through the hepatic system and therefore is susceptible to metabolism before it reaches the rest of the body. With a subcutaneous or intravenous injection this is not true, and the first passage of the compound to the other tissues of the body is in its unaltered state.
The question of how long the toxic agent stays in contact with susceptible tissue is also important. There may be delays in absorption or penetration that lead to prolonged, low tissue concentrations. This, of course, is a function not only of the absorption and metabolism, but also of two other major factors. The first is the excretory rate. Primary routes of excretion are renal and biliary. It is clear that the small mammals excrete compounds by the renal route much more rapidly than do large mammals (4). Biliary -excretion is a complex active process which has not been well studied in a comparative way (5) . One must take into consideration not only the immediate biliary excretion but also the potential reabsorption of the compound from the gastrointestinal tract after it has been excreted.
The distribution rate of the compound after absorption throughout the body is of major importance. This is well illustrated by the following facts: the cardiac output of the mouse is such that the blood volume is circulated 20 times per minute, while the cardiac output of man is such that the blood volume is circulated once per minute. Thus, the rate of distribution and mixing and delivery to the tissues of a compound within the body of a small mammal is very much more rapid than that in the body of a large mammal. Dedrick and co-workers have developed these principles in an important series of studies (6) .
The concept which follows from these comparative studies on metabolic alteration, Environmental Health Perspectivesexcretory rate, and distribution is consistent with the notion that small mammals dispose of (i. The last problem is one of the tissue target itself. There are really three aspects to this. The first concerns the problem of barriers between the general circulation and the susceptible cell or area within the cell. The blood-brain barrier is well known; the bloodtesticular barrier has been described by Dixon (8) ; other barriers may well exist within the body. Second is the question of the innate susceptibility of the cell. For example, Flamm describes the differences in repair mechanisms between bacteria in rodents and man (9) , which can influence the apparent innate susceptibility of the tissue target. Finally, I think it is important to consider the number-the quantity-of the susceptible cells in the test systems relative to those in man. This is particularly important when searching for a rare event. If an agent induces a mutation rate of 10-6 but there are only 104 cells available, it would be unlikely that a mutation would be detected. These considerations I think deserve much more attention than they have had in the past.
The last factor related to the toxic agent that I will discuss is the time-by this I mean the duration of the exposure. Chemical mutagenesis tests as currently designed consist of a brief exposure to the test animal or the test organism of the suspect compound. Very often, however, the real life situation is one of either a long-term, low-dose exposure or repeated small or moderate exposures. To what extent these are comparable I think is not known.
Another aspect of time is the ability of the human to accumulate compounds which are slowly excreted and/or metabolized over decades of exposure. For instance, in the mouse 2 ppm of DDT in the diet will yield, after about 11/2 yr of exposure, a concentration in the fat of 5 to 6 ppm of DDT and its metabolites (10) . This is about the same concentration present in the fat of the average U.S. citizen after decades of exposure at an exposure rate of about 0.015 to 0.04 ppm in his diet (11) .
In the process of comparing in vitro studies or laboratory animal studies with man, it is necessary to consider all of the factors mentioned above: those related to the toxic agent, those related to the target tissue, and those related to time. We (12) . Thus, knowledge of the average or median rate of drug disposition for the average man may not give much information as to the drug disposition rate of that 5%o or 1%o or 0.1%o of the population that is either "slow" or "fast."
We know there can be a very great variability in the actual exposure of environmental agents to man. We know that environmental effects themselves can affect metabolism, distribution, and excretion, as well as response, of foreign compounds, and these must be taken into consideration. Lastly, and perhaps most importantly, we must be particularly aware of the possibility of synergistic toxic interactions. It is well demonstrated for therapeutic drugs that one agent can drastically increase the toxicity of a second therapeutic agent. While this has not been well demonstrated for environmental agents, it seems very likely that it also occurs. Studies on synergistic toxicity might be ideal for in vitro methodology in which large numbers of compounds could be run alone and in combination very easily. It seems to me that, as we consider our test systems and the population that we want to protect, we must be aware of the toxic agent, the target cell, the time factor, and the variability factors. We must try very hard to achieve the same concentrations of the same chemical for the same time in the same tissues in the test systems as we do in man. When we have done that we have not yet succeeded, because we almost must anticipate the variability intrinsic in man and his complex way of life.
